Abstract
Livedoid vasculopathy is a rare chronic ischemic necrotic skin disease caused by microvascular thrombosis in superficial vascular plexuses. Effective treatments are lacking. Efficacy of anticoagulants has been clinically proven in the treatment of this disease, but the administration route and adverse reactions limit their extensive application. The new oral factor Xa inhibitor rivaroxaban, which has many advantages, such as no need for coagulation monitoring, few adverse reactions and convenient oral administration, can be used in the prevention and treatment of thrombosis and post-thrombotic ulcers. In this article, 3 patients with livedoid vasculopathy were treated with rivaroxaban alone or in combination, and satisfactory efficacy was obtained. Key words: Skin diseases, vascular; Anticoagulants; Treatment outcome; Livedoid vasculopathy; Rivaroxaban
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
